多黏菌素耐药性研究进展  

Research Progress of Polymyxin Resistance

作　　者：李立[1] 叶璟[1] 胡蕾[1] 谈林华[1] LI Li;YE Jing;HU Lei;TAN Linhua(Department of Surgical Intensive Care Unit,Children′s Hospital,Zhejiang University School of Medicine/National Clinical Research Center for Child Health,Hangzhou 310052,China)

机构地区：[1]浙江大学医学院附属儿童医院外科重症监护室,国家儿童健康与疾病临床医学研究中心,杭州310052

出　　处：《医学综述》2021年第17期3376-3382,共7页Medical Recapitulate

基　　金：国家中心自主设计项目全国多中心临床研究项目(G20B0009)。

摘　　要：多重耐药革兰阴性菌(GNB)引起的感染,特别是耐碳青霉烯的肠杆菌、铜绿假单胞菌和鲍曼不动杆菌引起的院内感染,在全球范围内引起严重的健康问题。多黏菌素作为一种阳离子多肽类抗生素,对多种GNB具有很强的杀菌活性。随着多黏菌素在人类和兽医中的大量使用,多黏菌素耐药菌株在世界范围内迅速出现,多黏菌素再次成为临床医师治疗多重耐药GNB感染的最后一线药物手段。对多黏菌素耐药性控制和预防策略的实施有赖于对其耐药机制和危险因素的进一步认识。Infections caused by multi-drug-resistant Gram-negative bacteria(GNB),especially the nosocomial infections that caused by carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii, are presenting significant health problems worldwide.Polymyxins, a family of cationic polypeptide antibiotics, are considered to be an antimicrobial of last-resort for the treatment of multidrug-resistant GNB infections.With the heavy use of polymyxins in human and veterinary medicine, polymyxin resistance has emerged rapidly in the world.The global dissemination of polymyxin resistance, has become an urgent public health threat.Implementing control and prevention strategies relies on an improved understanding of mechanisms and risk factors of polymyxin resistance.

关 键 词：多重耐药 多黏菌素 大肠埃希菌 铜绿假单胞菌 鲍曼不动杆菌 

分 类 号：R978.16[医药卫生—药品]